A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-09-01 DOI:10.1016/j.ygyno.2025.03.056

Yong Jae Lee , Yoo-Young Lee , Jeong-Yeol Park , Hyun-Woong Cho , Myong Cheol Lim , Mi-Kyung Kim , Jong-Min Lee , Eunyeong Yang , Jung-Yun Lee

引用次数: 0

查看原文本刊更多论文

诱导PD-1阻断剂（nivolumab）在手术可完全切除的错配修复缺陷子宫内膜癌（NIVEC）患者中的II期研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy